Summit Therapeutics
SMMT
222 hedge funds and large institutions have $2.25B invested in Summit Therapeutics in 2026 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 83 increasing their positions, 49 reducing their positions, and 37 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 49
57% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 37
9% more capital invested
Capital invested by funds: $2.06B → $2.25B (+$192M)
8% more funds holding
Funds holding: 206 → 222 (+16)
0.06% more ownership
Funds ownership: 15.27% → 15.34% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
15% less call options, than puts
Call options by funds: $39.9M | Put options by funds: $46.7M
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$45.4M |
| 2 |
D.E. Shaw & Co
New York
|
+$29.5M |
| 3 |
SCM
Superstring Capital Management
New York
|
+$14.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.7M |
| 5 |
Morgan Stanley
New York
|
+$11.7M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$32.9M |
| 3 |
PCMH
Polymer Capital Management (HK)
Hong Kong
|
-$20.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17.7M |
| 5 |
SC
Sculptor Capital
New York
|
-$6.24M |
SMMT Hedge Fund Activity: Q1 2026 in Review
222 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2026, worth a combined $2.25B — up 9.3% from $2.06B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new SMMT positions and 37 closed out — a net gain of 21 holders — while 83 added to existing stakes and 49 trimmed.
The largest buyer was UBS Group, adding an estimated $45.4M. The largest seller was Fidelity Investments, cutting an estimated $40.6M.
- 222 institutional investors held Summit Therapeutics (SMMT) as of Q1 2026, up from 206 in Q4 2025.
- Funds reported $2.25B of Summit Therapeutics stock for Q1 2026, up 9.3% quarter-over-quarter.
- 58 funds opened new Summit Therapeutics positions in Q1 2026 and 37 closed out, a net change of +21 holders.
- The largest Summit Therapeutics buyer in Q1 2026 was UBS Group, an estimated $45.4M added.
- The largest Summit Therapeutics seller in Q1 2026 was Fidelity Investments, an estimated $40.6M sold.
Based on aggregated 13F filings for Q1 2026.